Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

Certain soaps and other skin care products may irritate hidradenitis suppurativa (HS), whereas ... The American Academy of Dermatology (AAD) recommends that people with HS use an antibacterial ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

One key opportunity for growth of the hidradenitis Suppurativa market is the untapped potential found in emerging countries with growing healthcare infrastructure and treatment availability. This ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from povorcitinib treatment, Incyte announced in a press release.

Hidradenitis suppurativa (HS) is often misdiagnosed and dermatologists are working to educate everyone about the dangers of the painful, chronic skin condition. Kevyn Stewart reporting. Canadian ...

Fewer than half of respondents (46.9%) had a dermatologist as their primary ... in a large cohort with hidradenitis suppurativa. In Patients with HS, a Closer Look at Stigmatization and Perceived ...

according to a research letter published in Journal of the American Academy of Dermatology. New data showed that Bimzelx sustained disease control of hidradenitis suppurativa up to 2 years ...